|

Empagliflozin 25 MG Clinical Trials

11 actively recruiting trials across 1 location

Also known as: Jardiance, Jardiance (DIN: 02443945), Jardiance 25 MG, Jardiance® 25mg Film-Coated Tablets

Pipeline

Early 1: 2Phase 1: 3Phase 4: 4

Top Sponsors

  • The University of Texas Health Science Center at San Antonio4
  • National Taiwan University Hospital2
  • University Hospital, Basel, Switzerland1
  • Medanta, The Medicity, India1
  • McGill University Health Centre/Research Institute of the McGill University Health Centre1

Indications

  • Diabetes7
  • Type 2 Diabetes5
  • Heart Disease4
  • Heart Failure With Preserved Ejection Fraction2
  • End Stage Renal Disease on Dialysis2

Other7 trials

Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes
N/A
EMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal Disease
Phase 4
Effect of Empagliflozin vs Linagliptin on Glycemic Outcomes,Renal Outcomes & Body Composition in Renal Transplant Recipients With Diabetes Mellitus
N/A
Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia
Phase 4
Empagliflozin in Acute Heart Failure
Phase 4
Empagliflozin in Heart Failure with Reduced Ejection Fraction and End Stage Renal Disease
Phase 4
To Evaluate the Safety and Pharmacokinetic Interaction Between HODO-22251 and HODO-22252 in Healthy Adults
Phase 1

San Antonio, Texas4 trials

SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan

Texas Diabetes Institute - University Health System

Early 1
SGLT2i, Hepatic Glucose Production, and SNS

Texas Diabetes Institute/UH

Early 1
SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia

Texas Diabetes Institute/UH

Phase 1
SGLTi, Hepatic Glucose Production and Ketogenesis

Texas Diabetes Institute/UH

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.